1. Home
  2. NUS vs CABA Comparison

NUS vs CABA Comparison

Compare NUS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nu Skin Enterprises Inc.

NUS

Nu Skin Enterprises Inc.

HOLD

Current Price

$7.23

Market Cap

343.1M

Sector

Health Care

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.95

Market Cap

319.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUS
CABA
Founded
1984
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
343.1M
319.6M
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
NUS
CABA
Price
$7.23
$2.95
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$14.50
AVG Volume (30 Days)
365.3K
1.9M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
3.36%
N/A
EPS Growth
207.80
10.26
EPS
3.18
N/A
Revenue
$3,176,718,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.14
N/A
P/E Ratio
$2.30
N/A
Revenue Growth
48.98
N/A
52 Week Low
$5.63
$1.11
52 Week High
$14.62
$3.78

Technical Indicators

Market Signals
Indicator
NUS
CABA
Relative Strength Index (RSI) 40.70 46.28
Support Level $7.03 $2.32
Resistance Level $8.08 $3.34
Average True Range (ATR) 0.23 0.20
MACD -0.02 -0.04
Stochastic Oscillator 11.86 25.75

Price Performance

Historical Comparison
NUS
CABA

About NUS Nu Skin Enterprises Inc.

Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: